Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,638 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: One MORE Clear all

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Traumatic Brain Injury
Interventions: Progesterone, Placebo; Drug
Lead sponsor: David Wright; Other
Eligibility: 18 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more

Conditions: Pediatric Obesity
Interventions: Microbiome friendly diet; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 6 Years to 11 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: Education and Reminders, Educational Visit, Medication Educational Visit, Financial Support; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Patient Compliance, Medication Adherence, Medication Non-Adherence
Interventions: Information prescriptions; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 3,940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Diabetes
Interventions: Waitlist, Medically tailored meals - Daily delivery with human interaction, Medically tailored meals - Weekly delivery with no human interaction, Medically tailored meals - Standard MOWCTX delivery with human interaction; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 55 Years to 90 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Post-operative Pain
Interventions: Buprenorphine/Naloxone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus
Interventions: DSMES Intervention; Behavioral
Lead sponsor: Villanova University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Villanova, Pennsylvania

Conditions: Alcohol Dependence
Interventions: naltrexone, Broad Spectrum Treatment, Motivational Enhancement Treatment; Drug · Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Multiple Sclerosis
Interventions: Aerobic exercise, Stretching and toning exercise; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 59 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Covid19
Interventions: LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 98
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more

Conditions: Metastatic Breast Cancer
Interventions: Blood collection; Other
Lead sponsor: Janssen Diagnostics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Phoenix, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 14 more

Conditions: Opiate Dependence, Heroin Dependence
Interventions: depot naltrexone, Oral Naltrexone; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases
Interventions: Psychosocial Intervention, Structural Intervention, Traditional Psychosocial+Structural, Integrated Psychosocial+Structural; Behavioral · Other
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 25 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Depression, Psychological Stress, Affect
Interventions: Positive Affect Skills Training; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Chronic Conditions, Decision Making, Shared
Interventions: Patient Priorities Care, Usual Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: West Haven, Connecticut • Houston, Texas

Conditions: Saphenous Vein Graft Atherosclerosis
Interventions: Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label); Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 25
States / cities: Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Lispro low mixture; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 13
States / cities: La Jolla, California • Walnut Creek, California • New Britain, Connecticut + 10 more

Conditions: Hypertension
Interventions: Medication therapy management; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 19 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sepsis, Neonatal Mortality, Antibiotic Resistant Infection, Enteric Infections, Serious Bacterial Infection
Interventions: chlorination for water disinfection and surface disinfection, infection prevention and control messaging; Device · Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: Not listed
Enrollment: 45,450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Glaucoma
Interventions: Acetaminophen; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: Erdafitinib Intravesical Delivery System; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more

Conditions: Childhood Asthma, Community Health Workers
Interventions: Yes We Can Children's Asthma Program, School-Based Asthma Therapy, Open Airways for School Plus; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 13 Years
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cocaine Dependence
Interventions: Buprenorphine + Naltrexone, Placebo + Naltrexone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more

Search by objective public record fields.

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Progesterone for the Treatment of Traumatic Brain Injury III

Childhood Obesity Microbiome Study

Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)

Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients

Meals for Me: Drop Shipment Versus Personally-delivered Meals for Diabetes Management

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

Screening and Nutrition for Patients With Diabetes: A Pilot Study

Research on Individualized Treatment for Alcoholism

Study of Exercise on Impact of Cognitive Functioning in Multiple Sclerosis Patients

ACTIV-3: Therapeutics for Inpatients With COVID-19

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone

Nutrition360: Moving to Integrated and Holistic Disease Prevention Among Underserved Mississippians

Online Positive Emotion Skills Intervention for Symptoms of Depression

Effect of Patient Priorities Care Implementation in Older Veterans With Multiple Chronic Conditions

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin

Morning Versus Evening Dosing of Antihypertensive Medications: A Pilot Study to Assess Feasibility and Efficacy

Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates

Does Oral Acetaminophen Lower Intraocular Pressure?

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

West Philadelphia Controls Asthma

Cocaine Use Reduction With Buprenorphine